Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 2
2020 1
2021 4
2022 6
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2.
Uraki R, Kiso M, Iida S, Imai M, Takashita E, Kuroda M, Halfmann PJ, Loeber S, Maemura T, Yamayoshi S, Fujisaki S, Wang Z, Ito M, Ujie M, Iwatsuki-Horimoto K, Furusawa Y, Wright R, Chong Z, Ozono S, Yasuhara A, Ueki H, Sakai-Tagawa Y, Li R, Liu Y, Larson D, Koga M, Tsutsumi T, Adachi E, Saito M, Yamamoto S, Hagihara M, Mitamura K, Sato T, Hojo M, Hattori SI, Maeda K, Valdez R; IASO study team; Okuda M, Murakami J, Duong C, Godbole S, Douek DC, Maeda K, Watanabe S, Gordon A, Ohmagari N, Yotsuyanagi H, Diamond MS, Hasegawa H, Mitsuya H, Suzuki T, Kawaoka Y. Uraki R, et al. Among authors: okuda m. Nature. 2022 Jul;607(7917):119-127. doi: 10.1038/s41586-022-04856-1. Epub 2022 May 16. Nature. 2022. PMID: 35576972 Free PMC article.
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2.
Kawaoka Y, Uraki R, Kiso M, Iida S, Imai M, Takashita E, Kuroda M, Halfmann P, Loeber S, Maemura T, Yamayoshi S, Fujisaki S, Wang Z, Ito M, Ujie M, Iwatsuki-Horimoto K, Furusawa Y, Wright R, Chong Z, Ozono S, Yasuhara A, Ueki H, Sakai Y, Li R, Liu Y, Larson D, Koga M, Tsutsumi T, Adachi E, Saito M, Yamamoto S, Matsubara S, Hagihara M, Mitamura K, Sato T, Hojo M, Hattori SI, Maeda K, Okuda M, Murakami J, Duong C, Godbole S, Douek D, Watanabe S, Ohmagari N, Yotsuyanagi H, Diamond M, Hasegawa H, Mitsuya H, Suzuki T. Kawaoka Y, et al. Among authors: okuda m. Res Sq [Preprint]. 2022 Feb 24:rs.3.rs-1375091. doi: 10.21203/rs.3.rs-1375091/v1. Res Sq. 2022. PMID: 35233565 Free PMC article. Updated. Preprint.
Differences among epitopes recognized by neutralizing antibodies induced by SARS-CoV-2 infection or COVID-19 vaccination.
Yamamoto S, Yamayoshi S, Ito M, Sakai-Tagawa Y, Nakachi I, Baba R, Kamimoto S, Ogura T, Hagiwara S, Kato H, Nakajima H, Uwamino Y, Yagi K, Sugaya N, Nagai H, Saito M, Adachi E, Koga M, Tsutsumi T, Duong C, Okuda M, Murakami J, Furusawa Y, Ujie M, Iwatsuki-Horimoto K, Yotsuyanagi H, Kawaoka Y. Yamamoto S, et al. Among authors: okuda m. iScience. 2023 Jun 25;26(7):107208. doi: 10.1016/j.isci.2023.107208. eCollection 2023 Jul 21. iScience. 2023. PMID: 37448563 Free PMC article.
Immunological Correlates of Prevention of the Onset of Seasonal H3N2 Influenza.
Okuda M, Sakai-Tagawa Y, Koga M, Koibuchi T, Kikuchi T, Adachi E, Ahyoung Lim L, Yamamoto S, Yotsuyanagi H, Negishi K, Jubishi D, Yamayoshi S, Kawaoka Y. Okuda M, et al. J Infect Dis. 2022 Nov 11;226(10):1800-1808. doi: 10.1093/infdis/jiac152. J Infect Dis. 2022. PMID: 35478039 Free PMC article.
Antibody titers against SARS-CoV-2 decline, but do not disappear for several months.
Yamayoshi S, Yasuhara A, Ito M, Akasaka O, Nakamura M, Nakachi I, Koga M, Mitamura K, Yagi K, Maeda K, Kato H, Nojima M, Pattinson D, Ogura T, Baba R, Fujita K, Nagai H, Yamamoto S, Saito M, Adachi E, Ochi J, Hattori SI, Suzuki T, Miyazato Y, Chiba S, Okuda M, Murakami J, Hamabata T, Iwatsuki-Horimoto K, Nakajima H, Mitsuya H, Omagari N, Sugaya N, Yotsuyanagi H, Kawaoka Y. Yamayoshi S, et al. Among authors: okuda m. EClinicalMedicine. 2021 Feb;32:100734. doi: 10.1016/j.eclinm.2021.100734. Epub 2021 Feb 11. EClinicalMedicine. 2021. PMID: 33589882 Free PMC article.
Characterization of a new SARS-CoV-2 variant that emerged in Brazil.
Imai M, Halfmann PJ, Yamayoshi S, Iwatsuki-Horimoto K, Chiba S, Watanabe T, Nakajima N, Ito M, Kuroda M, Kiso M, Maemura T, Takahashi K, Loeber S, Hatta M, Koga M, Nagai H, Yamamoto S, Saito M, Adachi E, Akasaka O, Nakamura M, Nakachi I, Ogura T, Baba R, Fujita K, Ochi J, Mitamura K, Kato H, Nakajima H, Yagi K, Hattori SI, Maeda K, Suzuki T, Miyazato Y, Valdez R, Gherasim C, Furusawa Y, Okuda M, Ujie M, Lopes TJS, Yasuhara A, Ueki H, Sakai-Tagawa Y, Eisfeld AJ, Baczenas JJ, Baker DA, O'Connor SL, O'Connor DH, Fukushi S, Fujimoto T, Kuroda Y, Gordon A, Maeda K, Ohmagari N, Sugaya N, Yotsuyanagi H, Mitsuya H, Suzuki T, Kawaoka Y. Imai M, et al. Among authors: okuda m. Proc Natl Acad Sci U S A. 2021 Jul 6;118(27):e2106535118. doi: 10.1073/pnas.2106535118. Proc Natl Acad Sci U S A. 2021. PMID: 34140350 Free PMC article.
Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era, Japan, February 2020-March 2022.
Yamayoshi S, Iwatsuki-Horimoto K, Okuda M, Ujie M, Yasuhara A, Murakami J, Duong C, Hamabata T, Ito M, Chiba S, Kobayashi R, Takahashi S, Mitamura K, Hagihara M, Shibata A, Uwamino Y, Hasegawa N, Ebina T, Izumi A, Kato H, Nakajima H, Sugaya N, Seki Y, Iqbal A, Kamimaki I, Yamazaki M, Kawaoka Y, Furuse Y. Yamayoshi S, et al. Among authors: okuda m. Emerg Infect Dis. 2022 Nov;28(11):2198-2205. doi: 10.3201/eid2811.221127. Epub 2022 Oct 5. Emerg Infect Dis. 2022. PMID: 36198306 Free PMC article.
Anti-SARS CoV-2 IgG in COVID-19 Patients with Hematological Diseases: A Single-center, Retrospective Study in Japan.
Fujii T, Hagihara M, Mitamura K, Nakashima S, Ohara S, Uchida T, Inoue M, Okuda M, Yasuhara A, Murakami J, Duong C, Iwatsuki-Horimoto K, Yamayoshi S, Kawaoka Y. Fujii T, et al. Among authors: okuda m. Intern Med. 2022 Jun 1;61(11):1681-1686. doi: 10.2169/internalmedicine.9209-21. Epub 2022 Mar 26. Intern Med. 2022. PMID: 35342138 Free PMC article.
15 results